Can Insulet Stock Jump 50%?
Insulet (PODD) stock has historically seen large swings, with an 80% chance of a 50% jump in a given year. Its customer base grew over 20% in Q3 2026, driving a 19.2% revenue increase to $842 million. However, management expects slower growth in 2027. The stock trades at 3.3x sales and 24.7x earnings, with a $400 million buyback plan. Growth depends on customer retention and new product launches.
How this was made

The 30-second read
Why it matters
It highlights customer-base growth (>20% YoY) versus slower new starts (low single digits globally, flat U.S.), plus 2027 growth guidance moderation and a planned $400M Q4 buyback, setting up what to monitor for the next earnings release.
Market read
Traders can use the disclosed adoption metrics and the stated 2027 growth moderation to position ahead of the February 2027 fiscal Q4 results.
What to watch
The article does not quantify payer dynamics, reimbursement changes, or Omnipod 6 launch readiness, which could materially affect retention and future starts.
Background
The piece frames Insulet’s bull case as dependent on Omnipod’s installed base growth and retention, citing management commentary from the Nov. 4, 2026 call.
Ticker impact
Insulet management said global customer base grew more than 20% YoY in fiscal Q3 2026, while new starts rose only low single digits.
Likely two-way risk: upside if customer-base growth and retention re-accelerate, downside if new starts stay weak or rivals take share.
The article ties the bull case for a large stock jump to existing Omnipod users and highlights potential slip signals (eroding retention, slower new starts, competitive share loss).
Market effects
Diabetes device peers may see read-across on retention and competitive intensity in insulin pump adoption.
No specific regional market catalyst beyond international growth moderation guidance.
Limited, as the piece is company-specific and centered on Omnipod adoption metrics.
Counterpoint
Even with slower new starts, a stable or expanding installed base can still support revenue growth and buyback-driven EPS, reducing the probability of a sharp downside.
Key entities
- companyInsulet
Omnipod insulin pump maker; article focuses on customer-base growth, retention, competitive share, and 2027 guidance.
- productOmnipod
Insulin pump platform whose installed base and retention are presented as the key driver of potential large stock upside.
- productOmnipod 6
Next-generation pump expected to launch in 2027, cited as a factor that could influence future starts.

